CONFIDENTIAL First Amendment to License Agreement UML Agreement Ref. No. 370-092910
Exhibit 10.3
CONFIDENTIAL
First Amendment to License Agreement
UML Agreement Ref. No. 370-092910
This amendment is entered into between the University of Massachusetts, a public institution of higher education of the Commonwealth of Massachusetts as represented by its Lowell campus and Anterios, Inc. a Delaware corporation with an address of 000 Xxxx 00xx Xxxxxx (Xxxxx 0X), Xxx Xxxx, Xxx Xxxx 00000 and is made as of October 12, 2010.
Background
Anterios, Inc., formerly known as Encapsion, Inc. (“Company”), and the University of Massachusetts, a public institution of higher education of the Commonwealth of Massachusetts as represented by its Lowell campus (“University”) are parties to an exclusive license agreement (UML Agt. Ref. No. 334-050306) that was effective May 3, 2006 (“License Agreement”).
Company and University desire to amend the License Agreement for the purpose of, among other things, expanding the license granted by the University to Company to include additional intellectual property owned by University and to clarify the meaning of certain provisions as provided for in the License Agreement.
In consideration of the following, the Company and University agree as follows:
1. Capitalized terms used but not defined in this Amendment will have the meanings ascribed in the Licensed Agreement.
2. Section 1.3 “Field” is replaced in its entirety with the following:
“Field” means (a) all therapeutic or aesthetic purposes that require a prescription or administration by a licensed professional, including but not limited to, nutriceuticals, consumer health care, personal care and aesthetic/cosmetics, (b) all therapeutic or aesthetic purposes that do not require a prescription or administration by a licensed professional, including but not limited to nutriceuticals, consumer health care, personal care and aesthetics/cosmetics, (c) diagnostics and (d) industrial applications.
3. Section 1.4 “Licensed Product” is amended to replace the first sentence in its entirety with the following:
“Licensed Product” means any product that cannot be developed, manufactured, used, sold, or imported without infringing one or more claims under the Patent Rights.
4. Section 1.6 “Patent Rights” is amended to include the patent applications listed in Exhibit A-1, entitled “Patent Rights”, to this Amendment.
5. Within [*] business days of the full execution of this Amendment, Company will make a one-time payment to University of [*] as a licensing fee for the patent applications listed in Exhibit A-1 to this Amendment. Such fee is nonrefundable and is not creditable against any other payments due to the University under this Agreement.
6. With respect to the patent applications listed in Exhibit A-1 to this Amendment, University represents that it has incurred approximately [*] in connection with the filing, prosecution and maintenance of Patent Rights related to UMass Xxxxxx docket nos. UML 2005-017, UML 2006-019 and UML 2008-005 in out-of-pocket patent expenses as of the date of the Amendment. In respect of such expenses, and after receipt of the invoice(s) detailing such expenses, Company will make the following payments to University within the time periods specified:
[*] within [*] business days of the full execution of this Amendment;
[*] by [*]; and
[*] by [*].
7. Section 3.1(c) of the Agreement is revised to insert the following sentence:
The report shall provide specifics in sufficient detail as to Company’s progress in the development of Licensed Products in each segment of the Field to allow University to confirm timely completion of each diligence obligation per Section 3 of the License Agreement as amended.
8. Section 3.1(g) of this Agreement is replaced in its entirety with the following:
(g) Within [*] years and [*] months of the Effective Date, if Company has not made a first commercial sale of a Licensed Product for aesthetic purposes, the University may notice the Company of its intention to terminate the license granted under this Agreement only as it pertains to aesthetic/cosmetic purposes under Section 1.3(b) (definition of Field).
9. Section 3.1 of the Agreement is amended to insert the following as a new Subsection:
(h) With respect to Licensed Products utilizing the intellectual property claimed in the patent rights listed in Exhibit A-1 to this Amendment, Company will furnish to University by [*] a written development and commercialization plan (the “Plan”) under which Company intends to develop such Licensed Products that identifies the specific nature of the Licensed Products and a plan for their commercial development, covering at least one (1) indication for each subpart of the definition of Field. The parties hereby agree that said Plan will include specific commercially reasonable dates for making a first commercial sale of a Licensed Product which exploits each of those patent rights listed in Exhibit A-1 to this Amendment.
(i) If Company has not made a first commercial sale of a Licensed Product covering at least one (1) indication for each subpart of the definition of Field by the date indicated in the Plan (defined in (h) above), the University may notice Company of its intention to terminate the license granted under the License Agreement with respect to that subpart of the definition of Field.
(j) If Company has not made a first commercial sale of a Licensed Product for the treatment of cancer by the date indicated in the Plan (defined in (h) above), the University may notice Company of its intention to terminate the license granted under the License Agreement only as it pertains to those patent rights listed in Exhibit A-1 to this Amendment which are specifically directed to the treatment of cancer. For clarity these patent rights are UML 2005-017 and UML 2006-019. Company further agrees that in the event the License Agreement is terminated with respect to the treatment of cancer, Company agrees that it will negotiate in good faith with any subsequent University licensee to the UML 2005-017 and/or UML 2006-019 patent rights for a non-exclusive license under commercially reasonable terms to practice any other University owned or co-owned patent right for which it is the exclusive licensee, but only to the extent necessary to practice the UML 2005-017 and/or UML 2006-019 patent rights for the treatment of cancer.
10. In Section 3.1 of the Agreement, the last sentence of the final paragraph is deleted in its entirety.
(Deleted sentence with strikethrough as follows:
If the reason for non fulfillment of its obligations is lack of Company funds, Company has [*] months to fulfill the obligation, and the University may not exercise its right to terminate this Agreement or convert the exclusive license to non exclusive until the expiration of that [*] months.)
11. In Subsection 4.5(a), the table is deleted in its entirety and replaced with the following:
|
Subpart of Field |
|
Amount |
|
|
|
|
|
|
|
Therapeutic or aesthetic purpose that requires prescription or administration by licensed professional |
|
[*] |
|
|
|
|
|
|
|
Therapeutic or aesthetic purpose that does not require prescription or administration by licensed professional |
|
[*] |
|
|
|
|
|
|
|
Diagnostic |
|
[*] |
|
|
|
|
|
|
|
Industrial |
|
[*] |
|
12. In Subsection 4.5 (a) of the Agreement, the sentence following the table and immediately before subsection (b) is deleted in its entirety:
(Deleted sentence with strikethrough as follows:
If a particular Licensed product is a “Licensed Product” solely because it uses or incorporated Related Technology, the royalty rate applicable to that Licensed Product or Licensed Service is [*] of the royalty rate.)
13. For purposes of Section 10.10, all notices to Company shall be addressed as follows:
Anterios, Inc.
000 Xxxx 00xx Xxxxxx (Xxxxx
0X) Xxx Xxxx, Xxx Xxxx
00000
Attention: Xxx Xxxxxxx, M.D.
14. The parties each agree that the other is in full compliance with the terms and conditions of the License Agreement as of the date of their respective execution of this Amendment.
Other than the changes above, the terms and conditions of the Agreement remain unchanged and in full force and effect.
|
|
Accepted and Agreed: | |
|
|
| |
|
|
| |
|
|
ANTERIOS, INC. | |
|
|
| |
|
|
| |
|
|
By: |
/s/ Xxx Xxxxxxx |
|
|
|
Name: Xxx Xxxxxxx |
|
|
|
Title: CEO/President |
|
|
|
Date: Oct. 15, 0000 |
|
|
| |
|
|
| |
|
|
XXXXXXXXXX XX XXXXXXXXXXXXX | |
|
|
| |
|
|
| |
|
|
By: |
/s/ Xxxxxxx Xxxxxxxxx |
|
|
|
Name: Xxxxxxx Xxxxxxxxx |
|
|
|
Title: Executive Director |
|
|
|
Date: Oct. 22, 2010 |
Exhibit A-1
Patent Rights
|
Docket |
|
Inventors |
|
Title |
|
Patent/Patent |
|
UML 2005-017 |
|
Xxxxxxxx, Xxxx |
|
Anti-oxidant Synergy |
|
USSN 11/991,991 |
|
UML 2006-019 |
|
Xxxxxxxx, Tagne |
|
Composition and |
|
USSN 12/309,715 |
|
XXX 0000-000 |
|
Xxxxxxxx, Xxx, Xxxxxxxx, Lawton, Xxxxxxx |
|
Compositions and |
|
PCT/US2009/038835 |
